Filippo Lococo, Associate Professor of Thoracic Surgery presso Catholic University of the Sacred Heart – Unit of Thoracic Surgery, shared a post on LinkedIn:
“So proud to have concluded a very nice cooperation with Dana-Farber Cancer Institute of Boston (Published on CANCER DISCOVERY, I.F. 33, q1)
We provide a rationale for targeting TROP2 in EGFR-mutated NSCLC DTPs. In contrast to TROP2 ADC therapy, targeting of TROP2 with CAR-T cells can eliminate osimertinib-induced DTPs in vivo, revealing the promise of developing novel TROP2-based CAR-T cells to promote durable response and prevent disease relapse in patients.”
More from Filippo Lococo.